2021-07-18| Asia-PacificIPO

Could this Biotech be the First Billion-Dollar Hong Kong Startup to Go Public?

by Tyler Chen
Share To

Hong Kong’s Prenetics might be the first billion-dollar Hong Kong startup to go public. It is reported that Prenetics is planning a merger with a special purpose acquisition company (SPAC) called Artisan Acquisition (Artisan) by the end of 2021, for a value estimated to be over $1.3 billion.

Artisan has already raised $339 million in its initial public offering (IPO) and has obtained $60 million through forward purchase agreements with Aspex and PAG. However, it should be noted that it is not a done deal yet due to several factors that will come into play.


SPAC Explained

SPAC is a relatively new way to go public. The SPACs will go through the traditional IPO process to raise money and only use them to acquire or merge with a private firm. By doing so, the acquired company can evade the IPO process and be listed on the board through the SPAC’s shell. As a result, there has been an increasing number of SPAC deals in the biotech industry.


Prenetics’ Biggest Strength

Prenetics is well-known in the diagnostic and genetic testing industry, especially during the COVID-19 pandemic. The firm has installed COVID-19 screening devices in Hong Kong International airport and the London Heathrow Airport to accelerate the testing process of travelers.

Other than that, Prenetics in April announced a 3-year collaboration with the Oxford University to further develop Oxford’s rapid molecular testing technology for infectious diseases to deliver fast and accurate molecular testing globally.

Related Article: Oxford, Prenetics Join Forces To Scale Award-Winning Rapid Molecular Testing Technology


© All rights reserved. Collaborate with us:
Related Post
Prenetics Announces Acquisition of ACT Genomics, Aiming for the Multi-billion Market of Precision Oncology
CK Life Sciences and CK Hutchison Invest in Taiwanese Liquid Biopsy Candidate
Human Longevity Plans to Merge With Blank Check Company to Go Public
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
Comparing ESG Regulations in the U.S., the U.K., and the EU
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
Scroll to Top